250+ investors that invest in your industry and stage
Get 250+ investors tailored to your startup
  • Invest in your industry and stage
  • Emails & contact info included
  • Excel and CSV export
  • Automatically
Trusted by 3,000+ startups

Top 50 Biotechnology Angel Investors in United Kingdom

A list of 50 angel investors that invest in Biotechnology startups based in United kingdom. We rank investors based on the number of investments they made in Biotechnology companies from United kingdom. We update this investor list every month.

Top 50 Biotechnology Angel Investors in United Kingdom

Investor Biotechnology United Kingdom investments
Jonathan Milner 25
Nadav Rosenberg 5
Charlie Songhurst 3
Stefano Bernardi 3
DrPano Kroko Churchill 3
Jude Gomila 3
Milad Alucozai 3
Peder Nielsen 3
Darrin Disley 3
Ian Hogarth 3
Mark Evans 2
Pratima Aiyagari 2
Patrick Pichette 2
Jon Oringer 2
Jon Oringer 2
Ariel Poler 2
Chris Mairs 2
Edward Lando 2
Nicholas Edwards 2
Gilad Engel 2
Ed Parkinson 2
Hugh Grant 2
Jan Hruska 2
Serge Chiaramonte 2
Inaki Berenguer 2
Jon Oringer 2
Bradley Horowitz 2
Paul Wicks 2
Paul Forster 2
Nadav Ben-Chanoch 2
Tim Dempsey 2
Jim Mellon 2
Ahmed Medhat 1
Martin Chavez 1
Kristen Fortney 1
Pa Nolan 1
Mark Bamforth 1
Fiona Pathiraja 1
David Rowan 1
Mark McCamish 1
Brad Wilson 1
Abdulaziz Alrashed 1
Sami Mikati 1
Karl Wills 1
Taz Patel 1
Margaret Georgiadis 1
Chris Paul 1
Sunil Shah 1
Mark Gillespie 1
Chris Gibson 1
Find investors that fund startups like yours. Automatically.
Our algorithm will find investors that invest in your industry, stage, and geography.
Investor list
Jonathan Milner Angel · Cambridge, Massachusetts, United States · 3 investments in the past 12 months
Having worked in the life sciences industry for over ten years as an academic researcher, Jonathan identified the market opportunity for supplying high quality antibodies to support protein interaction studies and, in 1998, founded Abcam with David Cleevely and Professor Tony Kouzarides. Jonathan is a Non-Executive Director of Horizon DiscoveryGroup plc, The Evolution Education Trust, GeoSpock Ltd and Sydicate Room Group Ltd. He is also Chairman of Axol Bioscience Ltd, PhoreMost Ltd, Repositive Limited, Definigen Limited and Cambridge Allergy Ltd. Jonathan holds an executive director position at Meltwind Limited, being a designated member of Meltwind Advisory LLP. Jonathan is an experienced entrepreneur and investor and is passionate about supporting UK life science and high-tech start-ups. He has provided considerable investment and support to over 30 companies and has assisted three AIM IPOs.
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Seed, Series A, Series B
  • United Kingdom, United States, Canada
Portfolio highlights
  • Mogrify — Mogrify is pioneering a new class of in vivo reprogramming therapy and transforming the development of ex vivo cell therapy.
  • Pencil Biosciences — Next Generation Genome Editing Tool
  • Relation Therapeutics — Relation uses machine learning to develop drugs for pressing unmet need.
Nadav Rosenberg Angel · London, England, United Kingdom
Nadav leads Taboola’s expansion and operations in Europe and Australia.Prior to joining Taboola, Nadav was a member of the founding team of Groupon UK & IR, taking part in building and managing Groupon’s business in the UK.Before joining Groupon, Nadav worked as a strategy consultant with McKinsey & Company in London.Nadav isbased in London and holds an MBA from INSEAD, France.
Show more
Investment focus
  • Biotechnology, Artificial Intelligence, Pharmaceutical
  • Seed, Pre-Seed, Series A
  • United Kingdom, Israel, Singapore
Portfolio highlights
  • thymia — Making mental health as objectively measurable as physical health.
  • Exogene — Exogene is a biotechnology company accelerating the discovery of T-cell-receptor(TCR)-based cancer immunotherapies for solid tumours by combining deep learning and high-throughput TCR-antigen screening. Exogene is building a computational platform to quickly and inexpensively identify new tumour targets shared across cancer patients, as well assafe and effective TCRs against these tumour targets for therapeutic application. Their mission is to develop better TCR-based immunotherapies, faster and at a fraction of the cost.
  • Loops — With Loops causal insights you can identify your biggest opportunities to maximize your KPIs... try the Loops way
Charlie Songhurst Angel · Greater Seattle Area, Washington, United States · 10 investments in the past 12 months
Charles Songhurst is a founding partner of Katana Capital, a long-short equity hedge fund. He also runs the Songhurst Group, which holds assets in a variety of private companies.Charles ran corporate strategy for Microsoft and focused on partnering and M&A. He was involved in the Yahoo acquisition and commercial deal, and the Skypeacquisition. Before running corporate strategy, Charles was focused on the emergence of Google and the growth of the search industry.Prior, Charles was an analyst at McKinsey & Company in London. Charles received a bachelor’s degree from Oxford University in politics, philosophy, and economics.
Show more
Investment focus
  • Software, Information Technology, Artificial Intelligence
  • Seed, Pre-Seed, Funding Round
  • United Kingdom, United States, Germany
Portfolio highlights
  • Octomind — Octomind is an AI-powered end-to-end web app testing tool that detects bugs before they are discovered by users. It develops automated software that runs UI tests to discover bugs.
  • StackOne — Accelerate your SaaS growth with our unified API solution for HRIS, ATS, and CRM. Say "yes" to customers, build advanced integrations quickly, and experienced the best data privacy controls in the market.
  • Utila — Utila is an enterprise-scale self-custody platform that manages your organization's crypto strategy with safe, chain-agnostic wallet infrastructure.
Stefano Bernardi Angel · San Francisco, California, United States · 2 investments in the past 12 months
Stefano Bernardi is the Investment Director, Climate at Fondazione ENEA Tech.
Show more
Investment focus
  • Software, Biotechnology, Artificial Intelligence
  • Seed, Pre-Seed, Funding Round
  • Italy, France, Norway
Portfolio highlights
  • Freatic — We bridge the gap between individuals with untapped knowledge and actors who can take advantage of these opportunities.
  • Eden Bio — Eden Bio is a biotech using machine learning to guide the genetic engineering of microorganism strain optimisation, improving protein yield.
  • CaSRevolution — A novel disease-modifying approach against neurodegeneration
DrPano Kroko Churchill Angel · Seattle, Washington, United States
Pano Kroko is a legendary entrepreneur, Angel, VC and PE investor in innovation towards solving big problems. His investment emphasis is on Life Sciences, Biotech, Therapeutics, Medicine, Internet, Mobile, Communications, Clean Technology, Renewable Energy, and Environmental Finance. We have a quarterly Business Plan competition for placementin our early stage start up accelerator in Seattle Washington. We also run a program in Washington DC, and we have an Innovation Master Class Startup Weekend that runs Ten times a year in Seattle, Beijing, Silicon Valley, and in major Universities around the world.The Accelerator in Seattle & Silicon Valley is called American Angels, and the Accelerator in Washington DC is named H2O and both accept business plans and great ideas with Founders, and Executive teams right now. We would like to see StartUps in all of our areas of focus as well as anything else that is great and promising to solve Big Problems. Parallel to this we also run the CEP - Clean Energy Program incubator in Oxford UK, and the Biotech accelerator for genetics, stem cell applications, genomics, medicine, pharma and telomeres research in Cambridge UK.For our more traditional VC and PE work in the US, the American Venture Company in the US and the Investment Bank Green Capital Inc in the UK and Europe. These are our conduits of support for companies and also the Green Bonds Investments Plc. All of our organizations act as levers of positive change for impact investing, and as corporate environmental investment responsibility -- within the Finance community.In Seattle and in Silicon Valley we run the Accelerator and Early Stage Investment firm AMERICAN ANGELS where we have monthly pitches and demos for new StartUps and we also run a CEO roundtable to help promising Entrepreneurial leaders to succeed.If you or your company is interested in cooperation, presenting, funding, deal syndication or simply for submission of Executive Summaries and Business Plans for early stage angel funding and/or inclusion in the H2O Incubator/Accelerator or the Clean Energy program and the Biotech incubator, please contact us herewith: Mr Ruddy Wallace: envpar [at] gmail.com
Show more
Investment focus
  • Health Care, Therapeutics, Biotechnology
  • Angel, Series A
  • United Kingdom
Portfolio highlights
  • Amrit Advanced Biotech — Company working in Genetics, Telomeres health applications, cancer mitigation and lengthening of....
Jude Gomila Angel · San Francisco, California, United States · 2 investments in the past 12 months
Jude Gomila is currently CEO and Founder of the startup Golden.
Show more
Investment focus
  • Software, Biotechnology, Information Technology
  • Seed, Pre-Seed, Angel
  • United States, United Kingdom, Canada
Portfolio highlights
  • Parcha AI — Parcha is an AI-powered enterprise software that enables businesses to automate their scale compliance and operations.
  • HockeyStack — HockeyStack enables marketing teams to drive pipeline efficiently and sales teams to close deals faster with modern attribution, holistic buyer journeys, and account insights.
  • Gradia Health — Gradia is an integrated, concierge care platform designed for clinics to support patients with chronic conditions.
Milad Alucozai Angel · San Francisco, California, United States
Dr. Milad Alucozai is an Afghan-American neuroscientist, entrepreneur, biotech executive, and global investor with nearly two decades of experience in deep tech, primarily in life sciences. He pushes the boundaries of bioengineering and computational advancements, integrating machine learning and artificial intelligence into biology and medicine.With a strong commitment to commercializing transformative technologies and fostering startup ecosystems worldwide, he is a thought leader and formal mentor for entrepreneurs through organizations like Creative Destruction Lab and the Wyss Institute at Harvard Medical School.Currently, Milad is the head of Bio and Deep Tech at BoxOne Ventures, where he spearheads the firm’s investments in early-stage companies with breakthrough scientific ideas. With nearly 80 early-stage investments, they are recognized as one of North America’s most active venture firms. He is also a Venture Partner at Entrepreneur First, a global fund that has built over 500 companies from scratch with an enterprise value of $10bn. He supports founders with strategy, scaling, business development, securing growth capital, and leadership training, often being their first investor and guiding them from startup inception to IPOs or acquisitions.He started his career in translational neuroscience and multiphysics laboratories before transitioning into founding roles at biotech startups. He is part of the founding team at Mekonos, a San Francisco-based company creating a proprietary cell-engineering platform to support the future of cell and gene therapies. He was also part of the founding team at Corstem, which specialized in machine learning and artificial intelligence software and was later acquired by Circle Cardiovascular, a platform in over 1000 hospitals and more than 40 countries. At Accenture, Milad directed teams of data scientists, designers, and engineers in developing artificial intelligence platforms for global pharmaceutical companies and hospital networks.Milad serves as a Fellow in Healthcare Engineering at the Regenstrief Center. In 2020, he served as an External Advisor to AstraZeneca. He was recognized as a National Science Foundation Scholar and Macklin Fellow at Johns Hopkins Medicine. He graduated Phi Beta Kappa with a degree in Neuroscience from Purdue University’s Honors Program. As a George J. Mitchell Scholar, he completed his master’s in Immunology and earned his doctorate from the Richard M. Fairbanks School of Public Health.
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Seed, Series A, Pre-Seed
  • United States, Canada, United Kingdom
Portfolio highlights
  • Arpeggio Bio — We engineer medicine based not on a single target, but the biological network as a whole.
  • Future Fields — Future Fields Cellular Agriculture: Serum-Free Growth Media Supplements and Recombinant Proteins - Optimized for the Future of Food.
  • Eigen Therapeutics — Eigen Therapeutics is a biotechnology company developing combination therapeutics for cancer. The company is in the research and development of synergistic therapies that improve efficacy while reducing the toxicity of small molecule therapies and immunotherapies, enabling physicians to get access to novel drugs in areas of unmet medical needs.
Peder Nielsen Angel · Copenhagen, Hovedstaden, Denmark
Peder Nielsen - Member of the Global Advisors Network @ Global Bio Fund
Show more
Investment focus
  • Biotechnology, Machine Learning
  • Seed, Funding Round
  • United Kingdom
Portfolio highlights
  • Bactobio — At Bactobio, our mission is to create a safer and greener world by harvesting valuable metabolites from biological dark matter.
Darrin Disley Angel · Cambridge, Cambridgeshire, United Kingdom
Darrin Disley is the CEO, Director & Investor at Mogrify. He attended University of Cambridge.
Show more
Investment focus
  • Biotechnology, Health Care, Big Data
  • Seed, Series A, Funding Round
  • United Kingdom
Portfolio highlights
  • bit.bio — Bit.bio specializes in the fields of coding and biology that determine the identity of every human cell. Their mission is coding cells for health. To do so, we apply the principles of computation to biology. Bit.bio's current focus is to develop a scalable technology platform capable of producing consistent batches of every human cell. Thishas the potential to unlock a new generation of medicine: it will enable research and drug discovery to move on from inappropriate models and work with the cells that actually are affected by the human disease. A scalable platform of consistent cells will also be the basis for a new generation of cell and tissue therapies. To achieve our goals, we have assembled a team of pioneers in stem cells, cellular reprogramming, mathematical modeling, and cell therapy. Collaboration is at the heart of bit.bio. We are empirical, highly ambitious, and driven by a common purpose.
  • Mogrify — Mogrify is pioneering a new class of in vivo reprogramming therapy and transforming the development of ex vivo cell therapy.
  • Desktop Genetics — Desktop Genetics is an international biotechnology company established in 2012 to help researchers discover and treat the root genetic causes of human disease. Today, Desktop Genetics is a recognised leader in genome editing technology, staffed by dedicated team of genome editing experts, bioinformaticians and data scientists, driven by thereal-world impact of CRISPR technology.They have invested four years developing their core technology, DESKGEN AI, trained on the largest database of genome editing data in the world. DESKGEN AI powers their flagship DESKGEN CRISPR Library product range, which enables the work of their pharma, biotech and academic customers working in drug discovery and functional genomics. Desktop Genetics' tools and technologies are used by over 1800 organisations all over the world, and their projects contribute directly to several key partnerships to bring CRISPR into the clinic. The company has received awards from Fast Company, Kairos 50 and SxSW Interactive.
Ian Hogarth Angel · London, England, United Kingdom
Ian got a master's in machine learning at Cambridge and loves dystopian robot takeover narratives. Seven years ago, Ian realized being a choirboy came with no street cred, so he started DJing hip-hop, funk, drum & bass, and grime. Ian quit his job at Bain & Company, Singapore to start Songkick.
Show more
Investment focus
  • Software, E-Commerce, Internet
  • Seed, Pre-Seed, Series A
  • United Kingdom, United States, Germany
Portfolio highlights
  • Claimer — Claimer is a self-service application that gets credit claims done easily of money spent on research and development. Its platform empowers company owners and advisors to prepare their claims, without any specialist knowledge, no matter how big or small the claim. It also prepares and submits the amended tax return for free.Claimer was founded in2019 by Adam McCann and is headquartered in Croydon, United Kingdom.
  • Unitary — We detect harmful content with context-aware AI to keep brands and platforms safe online.
  • Fabric — One home for everything. A file explorer and workspace for the internet age. All your drives, clouds, notes, screenshots, links, and files automatically gathered into one self-organizing home. Never forget anything again.
Mark Evans Angel · London, England, United Kingdom
Mark is currently a Founding Partner and LP and Investment Committee member at Kindred Capital, a European Seed-Stage Venture fund, based in London. He was a General Partner at Balderton Capital/ Benchmark Europe from 2002 through 2015, and an EIR at Benchmark Capital in 1999/2000.He spent the prior 15 years @ Goldman Sachs, where hewas a General Partner and Management Committee member. He studied Economics at both University of Oxford and Queen's University in Canada.
Show more
Investment focus
  • Software, E-Commerce, Health Care
  • Series A, Seed, Series C
  • United Kingdom, United States, The Netherlands
Portfolio highlights
  • ONI — Where are you in your super-resolution journey? ONI is here to support you along your super-resolution journey Answer a few simple questions to discover key resources that can help you make the most of single-molecule imaging technology across a wide range of applications Products Gallery FAQs Subscribe to our mailing list
  • Ufonia — Ufonia is replacing routine patient healthcare interactions with next-generation automated phone calls.
  • Arctoris — Arctoris is a platform company headquartered in Oxford, with its US operations based in Boston and its APAC operations based in Singapore. Arctoris developed and operates a unique drug discovery platform powered by advanced robotics and data science combined with an experienced team of biotech & pharma veterans. Arctoris actively pursuesseveral drug discovery programs in oncology and neuro, while also providing access to its platform to select biotech and pharma partners. Arctoris' approach of data-driven drug discovery leads to higher chance of success, and an accelerated progression of programs towards the clinic.
Pratima Aiyagari Angel · London, England, United Kingdom
Pratima is a Venture Partner at Nauta Capital and is based in London. At Nauta, Pratima focuses on enterprise software and deep tech domains.Pratima has 18+ years of professional experience. She is a software developer by background and spent several years in Silicon Valley working on developing intelligent network services in the networkmanagement domain. Pratima joins Nauta from US-based cybersecurity-focused investment firm Paladin Capital. Previously, Pratima led investments and acquisitions at Cisco Corporate Development in Europe with a specific focus on ML/AI, Enterprise Collaboration and Silicon. During her investment career, Pratima led an investment or held board seats in Aimotive, Adbrain, Evrythng, Secure Code Warrior, decentriq, Dashbird, and several fund investments. She also managed investments in several companies including Behaviosec, Italtel, ip.access, and Corvil.Pratima received her MBA from INSEAD in France and an MS in computer science from the Virginia Polytechnic Institute and State University in the US. Pratima is a co-author of a US patent in the area of network device clusters and high availability.
Show more
Investment focus
  • Analytics, Cyber Security, SaaS
  • Seed, Pre-Seed, Series A
  • United Kingdom, France, Croatia
Portfolio highlights
  • Gardin — We believe in a world in which everyone has the right to access high quality, nutritious food that is good for you and for our planet. Our environmental issues are real, something, somewhere needs to change. Gardin promises to create the step-change required by deploying its technology.
  • Mindflow — Mindflow is a No-Code & AI-driven Automation & Orchestration Platform that enables all Enterprise Cyber IT Professionals to Automate Mundane tasks.
  • ESPROFILER — ESProfiler is an enterprise platform that empowers CISOs to prioritise threats, optimise spend & continuously maximise return on investment
Patrick Pichette Angel · London, England, United Kingdom · 4 investments in the past 12 months
Patrick Pichette currently Board Member at LightSpeed and Twitter. He is a former Google's chief financial officer, where he started in June of 2008. He has nearly 20 years of experience in financial operations and management in the telecommunications sector, including seven years at Bell Canada, which he joined in 2001 as executive vicepresident of planning and performance management.During his time at Bell Canada, he held various executive positions, including CFO from 2002 until the end of 2003, and was instrumental in the management of the most extensive communications network in Canada and its ongoing migration to a new national IP-based infrastructure.Prior to joining Bell Canada, Patrick was a partner at McKinsey & Company, where he was a lead member of McKinsey's North American Telecom Practice. He also served as vice president and chief financial officer of Call-Net Enterprises, a Canadian telecommunications company.Patrick earned a bachelor's degree in business administration from UniversitA© du Quebec A  MontrA©al. He holds a master's degree in philosophy, politics, and economics from Oxford University, where he attended as a Rhodes Scholar. He also serves on the board of Engineers Without Borders (Canada).
Show more
Investment focus
  • Software, Artificial Intelligence, Machine Learning
  • Seed, Series A, Series B
  • United Kingdom, Germany, United States
Portfolio highlights
  • Mobai — Provider of attack detection, image manipulation detection and authentication. Strong and successful research team on biometrics.
  • Kaedim — Kaedim’s product creates 3D content as easily as you can take a photo, 2D content, with your smartphone today.
  • Apheris — Build ML-powered products using data that spans organizational or geographical boundaries, while ensuring compliance with regulation.
Jon Oringer Angel · Miami, Florida, United States
Jon Oringer is the founder and chairman of Shutterstock.
Show more
Investment focus
  • Software, Information Technology, E-Commerce
  • Seed, Pre-Seed, Funding Round
  • United States, United Kingdom, France
Portfolio highlights
  • Skedway — The optimization hub for the Modern Enterprise - Visualize, integrate and manage every shared company asset in one place.
  • Zamp — We take care of sales tax, so you don't have to.
  • NewHomesMate — Find, compare and buy a new construction home - all in one place.
Jon Oringer Angel · New York, New York, United States
Jon Oringer is the founder and chairman of Shutterstock.
Show more
Investment focus
  • Software, Information Technology, Health Care
  • Seed, Pre-Seed, Series A
  • United States, France, United Kingdom
Portfolio highlights
  • Skedway — The optimization hub for the Modern Enterprise - Visualize, integrate and manage every shared company asset in one place.
  • Zamp — We take care of sales tax, so you don't have to.
  • NewHomesMate — Find, compare and buy a new construction home - all in one place.
Ariel Poler Angel · San Francisco, California, United States
Ariel Poler is the Co-Founder of Reveri Health. Ariel is an Internet entrepreneur, mentor, and investor. He was the founder of IPRO, the first web analytics company, and of Topica, one of the first email communities. Ariel was a board member of Kana Software, LinkExchange, Odeo, LOLapps, and StumbleUpon. He currently serves on the boards of FreedomFinancial Network, MixTent, Strava, and Scan Inc. Ariel’s angel investments include AdMob, Flixster, Slideshare, Xobni, RockYou, and Outright, BrightRoll, Instructables, Causes, Kongregate and NexTag. Ariel holds a B.S. in Mathematics with Computer Science from MIT and an MBA from Stanford University. He is originally from Venezuela and lives in San Francisco with his wife and three children.
Show more
Investment focus
  • Software, Social Media, Internet
  • Seed, Series A, Angel
  • United States, Mexico, United Kingdom
Portfolio highlights
  • Reloadly — Reloadly makes it easy for developers to connect with Mobile operator services. We are disrupting a Trillion dollar industry! Mobile Operators are stuck in old school business models, where most of the world is moving to open source platforms for developers to build amazing products. Reloadly is bridging the gap between mobile operators anddevelopers, and at the same time creating new sales channels for the 816 mobile operators around the world.
  • Openlytics — Openlytics is a visual analytics platform. It allows Data Workers to create pipelines for data transformation and analysis, in a visual way. Our mission is to empower everyone in the organization to solve data problems, without waiting for developers.Openlytics is an early-stage company, looking to build a founding team that can shape thedirection of the product. We’re seed-funded, remote-first, and hiring.If you're interested in learning more, email us at hello@openlytics.io.
  • humm — humm harnesses cutting-edge neuroscience into products that allow people to learn faster and perform better.humm is working to bring the incredible results of neuroscience research out of the lab and into non-invasive wearables that improve the quality of life for everyday people. Our first product is a clinically validated patch that you wearfor 15 minutes to get up to 90 minutes of improved working memory, by gently stimulating the signals in the part of the brain that controls your executive thinking. humm improves your ability to learn and be at your best, allowing people to reconnect with the joy of learning and challenge themselves to continue growing at any stage of life, whether it's for work or personal enjoyment!
Chris Mairs Angel · London, England, United Kingdom · 2 investments in the past 12 months
Chris Mairs - Venture Partner @ Entrepreneur First
Show more
Investment focus
  • Software, Financial Services, FinTech
  • Seed, Pre-Seed, Angel
  • United Kingdom, United States
Portfolio highlights
  • VitVio — VitVio is a platform built around AI and computer vision with the goal of improving efficiency and quality of care in operating rooms.
  • Quantly — LLM-enabled financial research at the speed of thought.
  • Borderless — Borderless is a workforce migration platform.It offers automation solutions that focuses on all aspects of hiring and onboarding of foreign workers, including recruitment, immigration, relocation, and compliance.
Edward Lando Angel · San Francisco, California, United States · 4 investments in the past 12 months
Edward Lando is the Founder of Pareto Holdings. He previously worked at Horizons School of Technology as a Co-Founder. Edward Lando attended the Wharton School.
Show more
Investment focus
  • Software, Information Technology, Health Care
  • Seed, Pre-Seed, Funding Round
  • United States, United Kingdom, France
Portfolio highlights
  • SiPay — Sipay is a next-generation financial technology company offering a comprehensive all-in-one financial services platform. It enables B2B, B2C, and Sipay as a Service (Embedded Finance) customers to address all their banking and financial needs without requiring any other partners.
  • Fun — Fun offers to build a product ecosystem that leverages cross-chain decentralized wallets on the Odsy blockchain.
  • Unicorn Auctions — Unicorn Auctions offers rare spirits auctions to buyers, sellers, and collectors. They provide ios and android apps in addition to their web bidding platform for digital auctions. To ensure examination of every asset listed, they must take physical possession of their items.
Nicholas Edwards Angel · Oxford, Oxfordshire, United Kingdom
Nick serves as the Chairman of Prescient’s Board of Directors. He holds a degree in physiological sciences from The Queen’s College, University of Oxford, and completed his training in clinical medicine (BM, BCh) at Green College (now Green Templeton College), University of Oxford. Nick practiced in the areas of cardiology and general surgerybefore joining Andersen Consulting (now known as Accenture), eventually becoming the global leader of Accenture’s pharmaceutical R&D business during his 18-year tenure. In 2005, he founded Kinapse to provide consulting and outsourcing services to the pharmaceutical industry. Nick served as Kinapse’s Chairman until the company was sold to HgCapital in early 2016.
Show more
Investment focus
  • Medical, Health Care, Life Science
  • Seed, Funding Round
  • United Kingdom
Portfolio highlights
  • Oxford Medical Products — Oxford Medical Products is a UK-based biotechnology start-up revolutionising the weight-loss treatment space with its hydrogel-based technology.
Gilad Engel Angel
Gilad Engel - Partner @ Target Global
Show more
Investment focus
  • Hardware, Analytics, Biotechnology
  • Seed, Pre-Seed
  • France, Israel, United Kingdom
Portfolio highlights
  • Joe — Joe is an financial service that reimburses and allows ALL expenses to be paid in several installments.
  • Gardin — We believe in a world in which everyone has the right to access high quality, nutritious food that is good for you and for our planet. Our environmental issues are real, something, somewhere needs to change. Gardin promises to create the step-change required by deploying its technology.
  • Fourier Optics — Fourier's Metasurface optical combiner seamlessly embeds inside everyday glasses' lenses.
Ed Parkinson Angel
Ed Parkinson
Show more
Investment focus
  • Software, Health Care, Life Science
  • Seed
  • United Kingdom
Portfolio highlights
  • Antiverse — Designing biologics for 100 challenging targets
Hugh Grant Angel · Saint Louis, Missouri, United States
Hugh Grant is President and Chief Executive Officer at Monsanto.
Show more
Investment focus
  • Biotechnology, Machine Learning
  • Seed, Funding Round
  • United Kingdom
Portfolio highlights
  • Bactobio — At Bactobio, our mission is to create a safer and greener world by harvesting valuable metabolites from biological dark matter.
Jan Hruska Angel
Jan Hruska
Show more
Investment focus
  • Medical, Health Care, Life Science
  • Seed, Funding Round
  • United Kingdom
Portfolio highlights
  • Oxford Medical Products — Oxford Medical Products is a UK-based biotechnology start-up revolutionising the weight-loss treatment space with its hydrogel-based technology.
Serge Chiaramonte Angel · London, England, United Kingdom · 2 investments in the past 12 months
Serge Chiaramonte
Show more
Investment focus
  • FinTech, Financial Services, Information Technology
  • Seed, Pre-Seed, Funding Round
  • United Kingdom, United States, France
Portfolio highlights
  • Trezy — Trezy is smart & simple software the helps you manage your business with real-time finance insights & automated cash-flow forecasting.
  • qomodo — Qomodo: La piattaforma BNPL innovativa. Rate a tasso zero, approvazioni veloci, transazioni sicure. Rivoluzionaria nell'acquisto per aziende e consumatori.
  • Borderless — Borderless is a workforce migration platform.It offers automation solutions that focuses on all aspects of hiring and onboarding of foreign workers, including recruitment, immigration, relocation, and compliance.
Inaki Berenguer Angel · New York, New York, United States · 3 investments in the past 12 months
Inaki Berenguer is the President and Co-founder at iPronics Programmable Photonics.
Show more
Investment focus
  • E-Commerce, Software, Financial Services
  • Seed, Angel, Pre-Seed
  • Spain, United States, United Kingdom
Portfolio highlights
  • Bankflip — Permissioned data technology to collect and process your customers' income, tax, employment & other relevant data & documents in real-time
  • Libera Bio — Libera Bio is a biopharmaceutical company devoted to the development of a new class of therapeutics to address unmet medical needs in cancer
  • Mable (Neurolytic Healthcare) — Neurolytic Healthcare provides personalized medicine for neurological conditions. Neurolytic Healthcare collects and extracts insights from a combination of genetic and biomarker data to enhance diagnosis and help clinicians decide on optimal treatment strategies for neurological conditions.The company delivers digitally and genomically-drivenmedical devices to improve the current treatment of migraine and other neurological disorders, including a diagnostic support tool, pharmacogenetic test, and a mobile app for migraine event prediction.
Jon Oringer Angel · Miami, Florida, United States · 2 investments in the past 12 months
Jon Oringer is the founder and chairman of Shutterstock.
Show more
Investment focus
  • Software, Information Technology, E-Commerce
  • Seed, Pre-Seed, Funding Round
  • United States, France, United Kingdom
Portfolio highlights
  • SLUSHY — Slushy is the ultimate app for free, paid, and subscription content. Create a exclusive creator profile and earn from your fans. Discover new trending videos and images and connect with our thriving community.
  • Skedway — The optimization hub for the Modern Enterprise - Visualize, integrate and manage every shared company asset in one place.
  • Unsloth AI — Easy finetuning for AI and LLMs. Open-source and for beginners. Get faster with Unsloth.
Bradley Horowitz Angel · Palo Alto, California, United States · 2 investments in the past 12 months
Bradley Horowitz is an Advisor and Vice President of Product Management at Google. Most recently he helped create Area 120, Google's incubator for internally-sourced innovation. He's led a large number of products, programs and initiatives at Google - including Google for Startups, Google Photos, Gmail, Google Voice, blogger, and GoogleNews.Before joining Google in February 2008, Horowitz was Yahoo's vice president of Advanced Development where he drove the acquisitions of Flickr and MyBlogLog, launched the Brickhouse incubator and developed new products like Yahoo! Pipes. Additionally, he was responsible for the company's initiative to open up its platform which included overseeing the Yahoo Developer Network (YDN).Previously, he was co-founder and CTO of Virage, where he oversaw the technical direction of the company from its founding through its IPO and eventual acquisition by Autonomy.Horowitz was a PhD candidate at the MIT Media Lab. While at the Media Lab, he worked on a number of topics related to computer vision, graphics and image processing, which resulted in a patented new technique for the recovery of structure, motion and camera parameters from video sequences.Horowitz holds an MS in Media Science from MIT and a BS in Computer Science from the University of Michigan.
Show more
Investment focus
  • Software, Information Technology, Health Care
  • Seed, Series A, Series B
  • United States, United Kingdom, Germany
Portfolio highlights
  • CUR8 — CUR8 is committed to establishing a global market for carbon reduction. Carbon removal methods include increased rock weathering, direct air capture, forests, construction, soil, biomass, oceans, and new technologies.
  • Mill — Meet the cleanest, easiest way to prevent food waste at home. Mill recycles your peels, bones, stalks, and forgotten leftovers.
  • Parcha AI — Parcha is an AI-powered enterprise software that enables businesses to automate their scale compliance and operations.
Paul Wicks Angel · London, England, United Kingdom
Paul is a neuropsychologist and expert in digital health, clinical trials, and patient centricity. For 13 years he led the R&D team at PatientsLikeMe, an online community for over 700,000 people living with medical conditions. Specialising in clinical research using the Internet, Paul shaped the scientific validity of the platform in generatinginsights from patient-generated health data, leading to over 110 studies including a patient-driven observational trial of lithium in ALS, numerous patient-reported outcome measures, a “dose-response” curve for the benefits of friendship between patients, and methods for patient-centered and virtual clinical trial designs.He sits on the editorial boards of the BMJ, BMC Medicine, JMIR, Digital Biomarkers and The Patient. Prior to joining PatientsLikeMe, Paul worked at the Institute of Psychiatry (King’s College London) studying cognition and neuroimaging in ALS, with a postdoc in psychological consequences of Parkinson’s disease.His work has been profiled by the BBC, NPR, CNN, BBC Radio 4, the Wall Street Journal, and the New York Times. In 2011 he was awarded MIT Technology Review’s TR35 “Humanitarian of the Year” award, recognized as a TED Fellow in 2012, and joined the inaugural FLIER Program at the Academy of Medical Sciences in 2019.
Show more
Investment focus
  • Real Time, Marketplace, Biotechnology
  • Seed, Series A
  • United Kingdom
Portfolio highlights
  • Sano Genetics — Sano Genetics is a user-centric genetic data marketplace that connects individuals directly to the research world. It act as ethical brokers to facilitate a direct connection between you and research institutions. The company was founded in 2017 and is headquartered in Cambridge.
Paul Forster Angel · 4 investments in the past 12 months
Paul Forster
Show more
Investment focus
  • Software, FinTech, Financial Services
  • Seed, Series A, Pre-Seed
  • United Kingdom, Germany, Spain
Portfolio highlights
  • Enzai — Enzai's AI governance platform allows you to build and deploy AI with confidence. Measure your progress in AI responsibility, and get actionable steps with our 3-minute maturity assessment.
  • Purple Dot — Sell More by Selling Earlier
  • Triple — The best payment data enrichment solution. Our API includes fraud detection, transaction enrichment, categorization, subscriptions, and carbon footprint.
Nadav Ben-Chanoch Angel · Miami, Florida, United States
Nadav Ben-Chanoch - Partner @ Pareto Holdings
Show more
Investment focus
  • Software, Information Technology, Health Care
  • Seed, Pre-Seed, Funding Round
  • United States, United Kingdom, France
Portfolio highlights
  • Swaap — We build the market-neutral AMM protocol.
  • micro1 — We help companies hire and manage the best software engineers easily.
  • Skedway — The optimization hub for the Modern Enterprise - Visualize, integrate and manage every shared company asset in one place.
Tim Dempsey Angel
Tim Dempsey is a Managing Partner at Epiphany Capital. He graduated from the University of Manchester.
Show more
Investment focus
  • Software, SaaS, Information Technology
  • Seed, Series A, Funding Round
  • United Kingdom
Portfolio highlights
  • Lunio — Drive performance marketing efficiency by cutting out invalid traffic across all paid marketing channels. Reach more users with the same ad spend.
  • Mitra bio — We are transforming skin-care by approaching ageing as a disease to be fought. We are developing a genetic and epigenetic discovery platform to help skincare companies find and develop new compounds that actually fight the root cause of skin ageing.
  • PPC Protect — Drive performance marketing efficiency by cutting out invalid traffic across all paid marketing channels. Reach more users with the same ad spend.
Jim Mellon Angel
Jim Mellon is an international investor with interests in several industries. After leaving Oxford, where he studied PPE, (Philosophy, Politics and Economics) he worked in Asia and the United States for two fund management companies, GT and Thornton, before establishing his own business in 1991. His business operations include two components, alisted fund management company called Charlemagne Capital, and an Asian mining group, Regent Pacific.In addition, Mr. Mellon is Co-Chairman of West African Minerals Corporation and Regent Pacific Group. He is on the board of a number of public quoted companies, including Brazilian Gold Corporation, Charlemagne Capital Limited, Manx Financial Group, Plethora Solutions, Polo Resources, Port Erin Biophara Investments Limited, and the Speymill plc. He is the life tenant of a trust which owns the Burnbrae Group, which has substantial assets in the biotechnology, financial services, property, mining and leisure sectors. Mr. Mellon spends most of his time working on startup ideas and investing. His book, “Wake Up!” was published in 2005; his second book "10 Investments for the Ten Years Ahead" was published in 2008. In 2012, he co-wrote "Cracking the Code" which focuses on the biotechnology sector and how to profit from it. Mr. Mellon lives in the Isle of Man, Brussels and Ibiza and is an honorary fellow of Oriel College, Oxford.
Show more
Investment focus
  • Biotechnology, Health Care, Food and Beverage
  • Series A, Seed, Funding Round
  • United States, United Kingdom, Israel
Portfolio highlights
  • Voxia — Amy collects and analyzes information from all over the web and provides actionable insights about your leads, prospects and clients, all in one click.
  • Monaco Foundry — We are a team of Serial Entrepreneurs, former Senior Government Advisors and Fortune 500 Executives. A global venture accelerator that invests in early to mid-stage companies and their growth through a unique sweat equity model.
  • The Duppy Share — The Duppy Share Caribbean Rum is the best rum for cocktails, mixed drinks and rum gifts. Try all our rum recipes, from rum and ginger to dark rum punch.
Ahmed Medhat Angel · San Francisco, California, United States
Ahmed Medhat - Research Scientist, Core Data Science @ Meta
Show more
Investment focus
  • Information Technology, Apps, Manufacturing
  • Seed, Pre-Seed
  • United States, United Kingdom
Portfolio highlights
  • Ntropy Network — Unlock the power of transactions. Our technology enables flexible and autonomous banking data cleansing, labeling and enhancement.
  • OASIS AI — All you do is talk. AI does the rest.
  • Grin Gaming — GrinData micro markets software leverages best-in-class high-frequency trading and machine learning to deliver reliable odds pricing on the most markets.
Martin Chavez Angel · New York, New York, United States · 2 investments in the past 12 months
Marty Chavez is executive vice president and chief financial officer of The Goldman Sachs Group, Inc. He is a member of the Management Committee, Firmwide Capital Committee, Firmwide Risk Committee and Steering Committee on Regulatory Reform. Marty is also a member of the Firmwide Hispanic/Latino Network and the Lesbian, Gay, Bisexual andTransgender Network.Marty first joined Goldman Sachs in 1993 in the J. Aron Currency and Commodities Division, where he was a senior energy strat until 1997. He returned to the firm as a managing director in Investment Banking Division Strats in 2005, becoming global co-head of Securities Division Strats and then global co-chief operating officer of the Equities Franchise. Prior to assuming his current role, Marty was chief information officer, responsible for the Technology Division and jointly responsible with divisional leadership for the firm’s global strategists. He was named partner in 2006.Prior to first joining the firm, Marty was co-founder and chief technology officer of Quorum Software Systems from 1989 to 1993. From 1997 to 2000, he was global head of energy derivatives at Credit Suisse Financial Products. In 2000, Marty co-founded Kiodex, Inc. and was chairman and chief executive officer until 2004.Marty serves on the Harvard Board of Overseers and is a Fellow of the New York Academy of Medicine.Marty earned a PhD in Medical Information Sciences from Stanford University in 1990, an SM in Computer Science from Harvard University in 1985, and an AB, magna cum laude, in Biochemical Sciences from Harvard College in 1985.
Show more
Investment focus
  • Health Care, Machine Learning, Biotechnology
  • Series A, Seed, Private Equity
  • United States, United Kingdom
Portfolio highlights
  • Hebbia — Hebbia's neural search lets you execute research 10X faster and 10X more accurately. Transform your productivity today.
  • Ochre Bio — Ochre Bio is developing therapies for the biggest liver health challenges.
  • VMind AI — VMind is a frontier technology company building artificial general intelligence (AGI).
Kristen Fortney Angel · San Francisco, California, United States
Kristen Fortney - CEO & Co-Founder @ BIOAGE LABS
Show more
Investment focus
  • Biopharma, Health Care, Therapeutics
  • Series A
  • United Kingdom
Portfolio highlights
  • Ochre Bio — Ochre Bio is developing therapies for the biggest liver health challenges.
Pa Nolan Angel
Pa Nolan
Show more
Investment focus
  • Medical, Delivery, Shipping
  • Seed, Funding Round
  • Ireland, United Kingdom
Portfolio highlights
  • SiSaf — SiSaf delivers on the promise of RNA therapeutics with Bio-Courier technology.
  • Scurri — Scurri is next generation delivery management software that puts retailers back in control. Explore our delivery management software today.
Mark Bamforth Angel · Boston, Massachusetts, United States
Mark Bamforth is the Operating Partner at Ampersand Capital Partners.
Show more
Investment focus
  • Health Care, Medical, Biotechnology
  • Series A, Seed, Funding Round
  • United Kingdom, United States
Portfolio highlights
  • Dxcover — Dxcover are a world leader in liquid biopsy and artificial intelligence for early detection of cancers and other diseases to improve survival and quality of life.
  • PneumoWave — Empowering Intervention and Prevention for Opioid-Induced Respiratory Depression
  • Thymmune Therapeutics — Thymmune Therapeutics is developing a machine learning-driven thymic cell engineering platform to restore normal immune function in aging and disease.
Fiona Pathiraja Angel · 4 investments in the past 12 months
Fiona is Managing Partner at Crista Galli Ventures, an early stage healthtech VC fund based in London and Copenhagen.
Show more
Investment focus
  • Health Care, Biotechnology, Wellness
  • Pre-Seed, Seed, Series A
  • United Kingdom, Germany, Armenia
Portfolio highlights
  • Juniver — Science-based recovery program for eating disorders. Free yourself from urges, strengthen your decision-making, and get back to living your life.
  • Bloom Money — Bloom Money is a savings club app designed to help growing communities in migrant communities and use technology to promote community, safety, and convenience.
  • Storia — Capture your thoughts and unleash your inner voice
David Rowan Angel · London, England, United Kingdom
David Rowan is editor of the UK edition of WIRED magazine, which won 2009 Launch of the David Rowan is Editor of the WIRED UK, the technology and trends magazine covering online brands, gadgets and the culture that surrounds them. David has reported on technology for The Times and Channel 4 News, the latter requiring him to illustrate the newiPod Video from the set of a porn shoot. He's also written for The Sunday Times and Telegraph Magazines, and edited the Guardian's on-line content. David has curated an exhibition of British creative talent at the Government's Cabinet Forum conference. He has also addressed the TEDs, and frequently contributes on Newsnight and the Today programme. He also writes a monthly column for GQ. David is in touch with many of the world's leading trend-setters and spotters. In presentations he looks at how the net is disrupting almost every sector, how apps change consumer behaviour and why 'social commerce' is killing traditional marketing. He reveals the 10 trends that will change your market in the next decade - and what you should be doing now to protect yourself.
Show more
Investment focus
  • Software, Artificial Intelligence, Information Technology
  • Seed, Pre-Seed, Funding Round
  • United Kingdom, Germany, Croatia
Portfolio highlights
  • EWOR — EWOR is a blend of a master’s degree and venture capital firm investing €75K to €150K, connecting you with unicorn founders, and offering over 20 unique entrepreneurship courses.
  • Climate X — Climate X combines climate science and econometrics to deliver precise climate risk data without any black boxes.
  • Rhizocore Technologies — We develop high-performance strains of locally-sourced mycorrhizal fungi to improve tree growth, tree health and tree resiliency. We offer a sustainable solution to increase forest yields whilst improving the ability of trees to sequester carbon.
Mark McCamish Angel · Ventura, California, United States
Dr. McCamish is President and Chief Executive Officer of IconOVir Bio. Previously he was President and Chief Executive Officer of Forty Seven, Inc. He led Forty Seven, Inc. during critical phases of clinical development to help patients defeat their cancer. This included growing from a valuation of $169 million as a private company through a SeriesB offering, Initial Public Offering, two secondary fund raises and finally the acquisition of Forty Seven by Gilead for $4.9 Billion.He is an international expert in biologic and biosimilars development and manufacturing. Mark is passionate about mentoring and developing people while focusing on meeting patient needs through efficient, commercially viable efforts. He is a senior executive with extensive experience at multiple companies including Abbott, Amgen, and Novartis/Sandoz. He led pioneering efforts in filing/launching biosimilars worldwide. He has demonstrated a commercial mindset in establishing research and development strategies leading to approvals and commercial success in multiple therapeutic areas and regulatory categories including biologics, biosimilars, drugs, devices, and medical foods.He received Bachelor’s and Master’s degrees from UCSB and, after completing his PhD in Human Nutrition from Penn State and MD from UCLA, he completed Residency and Fellowship Training at the University of California, Davis. He held professorships at UC Davis and The Ohio State University
Show more
Investment focus
  • Medical, Biopharma, Biotechnology
  • Seed
  • United Kingdom
Portfolio highlights
  • Nemesis Bioscience — Nemesis Bioscience is a UK-based biopharmaceutical company developing products to resurrect anti-microbial therapies made ineffective by increasing microbial resistance. The company develops Nemesis Symbiotics that will make existing antibiotics work again, prevent the spread of resistance genes, and so also protect the efficacy of new antibiotics.The technology is applicable to all antibiotic classes, all known resistance mechanisms and all bacteria.Other applications include reduction of chemotherapeutic toxicity, inactivation of virulence factors, and in vivo synthesis of biofuels and therapeutics.The company was awarded the King’s College, Cambridge Entrepreneurship Award for 2014 and has filed patent applications internationally on its inventions.
Brad Wilson Angel · Plymouth Meeting, Pennsylvania, United States
Brad Wilson Global Product Director at GlaxoSmithKline.
Show more
Investment focus
  • Health Care, Biotechnology, Machine Learning
  • Seed
  • United Kingdom
Portfolio highlights
  • OxCan — Enabling curative cancer treatment through early detection
Abdulaziz Alrashed Angel
Abdulaziz Alrashed.
Show more
Investment focus
  • Analytics, Biotechnology, Information Technology
  • Seed
  • United Kingdom
Portfolio highlights
  • Gardin — We believe in a world in which everyone has the right to access high quality, nutritious food that is good for you and for our planet. Our environmental issues are real, something, somewhere needs to change. Gardin promises to create the step-change required by deploying its technology.
Sami Mikati Angel
Sami Mikati is a Director of Synthace Ltd. Investor and commercial executive with deep experience and network across energy and engineering industries in Europe, the Middle East and Africa.
Show more
Investment focus
  • Biotechnology, Software, Life Science
  • Seed
  • India, United Kingdom
Portfolio highlights
  • CyGenica — CyGenica uses a non-viral, non-toxic platform to develop in vitro and in vivo delivery solutions for drugs, gene editing components, and antibiotics.
  • Synthace — The Synthace Experiment Platform lets you design powerful experiments, run them in your lab, & gather automatically structured datasets. No code necessary.
Karl Wills Angel
Originally at MetaPack in 2000, Karl returned in November 2009 to take on the role as COO and CIO responsible for MetaPack’s Product Development, Support, Infrastructure and Carrier Integration. Karl is now responsible for handling MetaPack's legal activity and ensuring best practice is brought into all parts of the MetaPack operation toensure exceptional performance for our customers. In between the MetaPack roles, he worked for Abacus Billing as CEO before its sale to Mind CTI, successfully managing the company turnaround at Solution 1 as COO and interim CEO where he focused on improving their delivery function as well as their IT infrastructure.Prior to joining MetaPack that he has held roles such as Senior Supply Chain Director for EMI Records (based in The Netherlands), IT Director for EMI Operations and IT Director EMI France as well as a number of other UK and European IT and Logistics roles. This provides Karl with over 30 years experience in general management and the IT, logistics and warehouse industry.
Show more
Investment focus
  • CRM, Farming, Agriculture
  • Seed
  • United Kingdom
Portfolio highlights
  • Bionema — Leading UK biopesticides technology developer, specialising in organic and natural farming products, biological crop protection for safe and sustainable agriculture.
Taz Patel Angel · San Francisco, California, United States
Taz Patel is a serial entrepreneur with multiple exits over the past decade who continues to support the startup ecosystem via mentorship, advisory and investing. Most recently, Taz co-founded Captiv8, an Influencer marketplace and SaaS platform funded by Social Capital, Liquid 2, Visionnaire, Jason Calacanis, Cyan Banister and strategic Angels.Before this, Taz was the Chief Revenue Officer of Republic Project, a startup funded by Google Ventures and later acquired by DG Sizmek in 2013. Before that, Taz led monetization efforts at Showyou App funded by True Ventures that was acquired by Vevo in 2015. His knowledge in social marketing, mobile/video advertising, and SaaS/Marketplace businesses is a personal passion that stems from early sales leadership roles at Interclick and BlueLithium, both of which were acquired by Yahoo! for $270 Million in 2011 and $300 Million in 2007. A Chicago native, Taz studied at the University of California, Berkeley and currently lives with his wife, son and dog in San Francisco.
Show more
Investment focus
  • SaaS, Information Technology, Mobile
  • Seed, Series A, Funding Round
  • United States, United Kingdom
Portfolio highlights
  • CloudAdmin.io — CloudAdmin is a cost-optimization platform that helps executives save money in hidden cloud instance buying options.
  • Ampleforth — Ampleforth is the name of a character in George Orwell's 1984 who is responsible for translating poetry into Newspeak, a language designed to limit freedom of thought. When tasked to replace the word “God” in a Kipling poem, Ampleforth refuses, not out of righteousness, or subversiveness, but rather, a simple love for language and respect forthe truth. To Ampleforth, no other word makes sense in context and therefore no other word should replace it.
  • Marigold Health — Marigold Health is an anonymous social network where people with mental health and substance use conditions support each other.
Margaret Georgiadis Angel · San Francisco, California, United States
Margaret Georgiadis currently works as CEO-Partner and Co-Founder for Flagship Pioneering. She previously worked at General Catalyst as Endurance Partner In Residence. Margaret Georgiadis attended Harvard University
Show more
Investment focus
  • Health Care, Apps, Wellness
  • Seed, Series A, Series B
  • United States, United Kingdom
Portfolio highlights
  • OneRoof — OneRoof is an app that helps meet people with similar interests living in your building and build new friendships. Communication should go further than a nod in the elevator.
  • ShareWell — Struggling with mental health? ShareWell provides online peer support, a proven mental health alternative for therapy. Get group support when you need it.
  • Bridge Money — The path towards upward economic mobility.
Chris Paul Angel · San Francisco, California, United States
Christopher Emmanuel Paul is an American professional basketball player for the Oklahoma City Thunder of the National Basketball Association.
Show more
Investment focus
  • Food and Beverage, Sports, Health Care
  • Seed, Funding Round, Series A
  • United States, France, Portugal
Portfolio highlights
  • Scout - Make Money Moves — Scout is the financial wellness platform for student athletes in the new NIL era. We empower athletes to make better financial decisions with live financial education sessions and personalized, tech-enabled service.
  • Buoy — Zero sugar liquid electrolytes and ionic trace minerals that blend with any beverage, even alcohol and coffee. No sugar, no stevia, no dextrose, no flavorings and no artificial ingredients. Gluten and major allergen free. Vegan and non-GMO.
  • Umaro Foods — Umaro Foods specializes in developing a plant-based protein source from ocean-farmed seaweed.
Sunil Shah Angel · Cambridge, Cambridgeshire, United Kingdom
Sunil Shah is the CEO and Co-Founder of o2h group. He previously worked at India-UK Cancer Research Initiative (CRUK-DBT) as an Advisory Panel Member. Sunil Shah attended the University of Cambridge.
Show more
Investment focus
  • Health Care, Biotechnology, Pharmaceutical
  • Seed, Series A, Post-IPO Equity
  • United Kingdom
Portfolio highlights
  • Kuano — Kuano provides innovative quantum and AI solutions for drug discovery and design. It offers a discovery platform that combines target quantum mapping and AI-led chemistry to enable the faster development of better drug candidates.
  • PhoreMost — PhoreMost is a new-model drug discovery company based in Cambridge, UK: Using its core expertise to open up new ‘druggable’ target space and working with a global network of co-invested academic and industrial collaboration partners, we aim to bring a wide array of novel ‘targeted’ therapies more efficiently to market and pass these cost savingsonto patients.
  • Five Alarm Bio — Five Alarm Bio is a drug discovery company. Five Alarm intends to use discoveries to provide secure and efficient remedies for a variety of age-related illnesses and limitations. Five Alarm Bio is creating a small molecule strategy to strengthen the body's defense against aging.
Mark Gillespie Angel · Los Angeles, California, United States
Recently named as one of Billboard’s 2021 Change Agents, as well as one of the World's Greatest Managers by Music Business Worldwide, Mark Gillespie is a world-class British CEO, manager, and producer whose vision and drive have led him to build Three Six Zero into the global entertainment powerhouse that it is today. Widely recognized as oneof the industry's preeminent executives, Gillespie has been instrumental in guiding the careers of Frank Ocean and Calvin Harris, most recently closing a deal in excess of $100MM for his publishing catalogue. With offices in Los Angeles, Miami, and London, Gillespie provides the leadership necessary to ensure that Three Six Zero and its clients remain at the forefront of the music, film, television, and digital content landscapeFueled by a lifelong passion for music, Gillespie launched his career in his hometown of Birmingham, UK, where he proved to be an invaluable asset for superclub Godskitchen. Since then, he has established himself as a visionary in the entertainment industry, having worked in partnerships with Sony Music Entertainment, Jay-Z and Roc Nation, and most recently Westbrook Entertainment, whose talent roster includes Will Smith, Jada Pinkett Smith, and the entire Smith Family.A relentless pioneer and entrepreneur, Gillespie has joined forces with Pete Tong MBE to run Three Six Zero Recordings, his own in-house record label, while continuing to expand an already successful presence in film and television. Along with several other projects in the pipeline, the company's first feature film – prestige drama, VOX LUX – starring Natalie Portman and Jude Law, including an original soundtrack by Sia, was released in 2018.With a passion for innovation at the intersection of media, technology, and apparel, Gillespie has invested in companies such as Outdoor Voices, Stance, Ember Technologies, Stem Disintermedia, and Saavn. Committed to giving back and continuously fostering artistic talent, Gillespie has also remained a longtime philanthropist and advocate, sitting on both the Music Committee of Children in Conflict and the core screening panel of the Recording Academy. In his downtime, Gillespie enjoys following Manchester United and is an avid collector of modern art.
Show more
Investment focus
  • Music, Internet, Video
  • Funding Round, Seed, Series B
  • United States, United Kingdom, India
Portfolio highlights
  • Bkstg — Bkstg was founded by tech and music entrepreneurs to reinvent the way artists and fans connect by creating a new form of direct relationship that’s never existed before.
  • Hyperice — HyperIce is a recovery and movement enhancement technology company specializing in vibration, percussion, and thermal technology. Its technology is used by the athletes in professional and collegiate training rooms and fitness facilities globally.The company is driven by a mission to provide everyone with the innovative technology in acceleratingrecovery time, preventing injury, and enhancing the body’s ability to move efficiently. HyperIce was founded in 2010 by Anthony Katz.
  • Biosceptre — A Promise Beyond Cancer Envisioning the future of targeted therapeutics Biosceptre is driving innovation to bring new and progressive therapies to a wide range of cancer patients. Our focus is a multiple-targeted universal CAR T system with the potential to improve the lives of millions of patients across the world who are suffering from
Chris Gibson Angel · Salt Lake City, Utah, United States · 3 investments in the past 12 months
Chris Gibson is the Co-Founder and CEO of Recursion (Recursion Pharmaceuticals). He previously worked at Cure HHT as a Member Board of Directors. Chris Gibson attended the University of Utah.
Show more
Investment focus
  • Biotechnology, Health Care, Life Science
  • Series A, Seed
  • United States, France, United Kingdom
Portfolio highlights
  • Noetik — Noetik is an AI-native biotechnology company. Our mission is to leverage advanced machine learning methods to discover and develop cancer immunotherapies.
  • Amenities Health — Amenities is the healthcare industry's leading Digital Front Door and patient loyalty platform. We help healthcare providers to acquire new patients and upgrade them to members. Our all-in-one patient app works with most modern EMRs to: 1) register new users into a full EMR account in <30 seconds with full identity verification and noduplicates, 2) help those patients find care options and book appointments with simple, conversion-optimized workflows, 3) seamlessly integrates key patient portal and 3rd party functions (i.e., video visits, secure messaging, test results, and billing), and 4) upgrade patients to members with custom experiences and services offerings (i.e., for Medicare Advantage, concierge memberships, direct-to-employer, or direct primary care patients)
  • Cradle — Design better proteins
Investors by industry
Investors by country
Angel Investors in United Kingdom by industry